Eversept Partners LP Cuts Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Eversept Partners LP cut its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 91.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 343,400 shares of the company's stock after selling 3,761,913 shares during the quarter. Eversept Partners LP owned approximately 0.40% of Syndax Pharmaceuticals worth $4,540,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Assenagon Asset Management S.A. raised its position in Syndax Pharmaceuticals by 343.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after purchasing an additional 1,598,428 shares during the period. Renaissance Technologies LLC purchased a new stake in Syndax Pharmaceuticals during the fourth quarter valued at about $9,002,000. Trexquant Investment LP grew its stake in shares of Syndax Pharmaceuticals by 1,309.7% during the fourth quarter. Trexquant Investment LP now owns 471,292 shares of the company's stock valued at $6,230,000 after buying an additional 437,859 shares during the last quarter. Altium Capital Management LLC purchased a new position in shares of Syndax Pharmaceuticals in the fourth quarter worth about $4,891,000. Finally, Walleye Capital LLC lifted its stake in shares of Syndax Pharmaceuticals by 831.3% in the 4th quarter. Walleye Capital LLC now owns 364,750 shares of the company's stock valued at $4,822,000 after acquiring an additional 325,585 shares during the last quarter.

Syndax Pharmaceuticals Stock Performance

Shares of Syndax Pharmaceuticals stock traded up $0.03 during trading on Friday, hitting $13.33. 756,269 shares of the company's stock were exchanged, compared to its average volume of 1,595,894. Syndax Pharmaceuticals, Inc. has a 52-week low of $9.66 and a 52-week high of $25.07. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.67 and a beta of 1.28. The business has a 50-day simple moving average of $13.10 and a 200-day simple moving average of $14.93.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analysts' expectations of $86.32 million. On average, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SNDX has been the topic of several analyst reports. Citigroup decreased their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Scotiabank cut their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday, April 10th. JPMorgan Chase & Co. increased their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.20.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the sale, the chief financial officer now owns 90,746 shares in the company, valued at approximately $1,406,563. This represents a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares of the company's stock, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,683 shares of company stock worth $336,087 in the last 90 days. Insiders own 4.10% of the company's stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).